WebJun 28, 2024 · 28 June 2024, 9:32 am · 4-min read. OPKO Health, Inc. OPK recently announced that its subsidiary EirGen Pharma has inked a deal with Nicoya Macau Limited, an affiliate of Nicoya Therapeutics (Nicoya), for the development and commercialization of RAYALDEE in Greater China. RAYALDEE is used to treat secondary hyperparathyroidism … WebNephrology. Our lead nephrology product, Rayaldee ® (calcifediol), is approved by the U.S Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3-4 chronic kidney disease (CKD) with vitamin D insufficiency. A phase 2 clinical trial to evaluate the safety and efficacy of Rayaldee® to treat SHPT is …
OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19
WebSep 15, 2024 · OPKO expects to report topline results from this Phase 2 trial before year-end. About RAYALDEE. RAYALDEE is an extended-release oral formulation of calcifediol, … WebVifor Fresenius Medical Care Renal Pharma (VFMCRP), a common company of Galenica and Fresenius Medical Care, and OPKO Health ( OPK ), have entered into a collaboration and license agreement for the development and commercialization of RAYALDEE® in Europe, Canada, Mexico, Australia, South Korea and certain other international markets for the ... date to wk number
RAYALDEE Loss of Exclusivity (LOE). When do the patents on …
WebJul 7, 2016 · By Cynthia Ritter • July 7, 2016. The vitamin D prohormone drug RAYALDEE (OPKO Health, Inc.) has been approved by the FDA for treatment of secondary … WebFeb 24, 2024 · Which patents cover Rayaldee, and when can generic versions of Rayaldee launch? Rayaldee is a drug marketed by Eirgen and is included in one NDA. There are … WebAbout Rayaldee® Rayaldee ® (calcifediol) is an extended-release prohormone of the active form of vitamin D 3 that both raises 25-hydroxyvitamin D and lowers intact parathyroid … date to year